Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Structural genomics: bridging functional genomics and structure-based drug design.

Sean G Buchanan1

  • 1sean@stromix.com

Current Opinion in Drug Discovery & Development
|June 13, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of KRAS<sup>G12C</sup> inhibitor olomorasib single-agent and combination with activity in KRAS<sup>G12C</sup>-mutant models.

Nature communications·2026
Same author

Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders.

Nature cancer·2021
Same author

The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.

Cancer discovery·2020
Same author

Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells.

Oncotarget·2020
Same author

Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy.

Molecular cancer therapeutics·2019
Same author

Unraveling the genomic determinants of response to CDK4/6 inhibitors.

Oncotarget·2019

Structural genomics advances integrate high-throughput biology and computational methods for drug discovery. These innovations, including NMR and X-ray crystallography, are rapidly adopted by the biopharmaceutical industry.

Area of Science:

  • Structural biology
  • Genomics
  • Drug discovery

Background:

  • Recent progress in structural genomics has led to new centers and pilot studies.
  • Genome sequencing efforts have provided high-throughput molecular biology and genome sequence data for structural genomics.

Purpose of the Study:

  • To review recent results from structural genomics initiatives.
  • To explore the potential applications of new information and technologies in drug discovery.

Main Methods:

  • Integration of high-throughput molecular biology and whole-organism genome sequences.
  • Advancements in Nuclear Magnetic Resonance (NMR) spectroscopy and X-ray crystallography.
  • Development of new methods in structural bioinformatics and computational chemistry.

Related Experiment Videos

Main Results:

  • Significant advances in NMR spectroscopy and X-ray crystallography.
  • Publication of new bioinformatics and computational chemistry methods.
  • Adoption of structural genomics developments by the biopharmaceutical industry.

Conclusions:

  • Structural genomics is rapidly advancing, providing valuable tools for drug discovery.
  • The integration of genomics and structural biology offers new avenues for pharmaceutical research and development.